Welcome to our dedicated page for Aveanna Healthcare Holdings SEC filings (Ticker: AVAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aveanna Healthcare Holdings Inc. (AVAH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Aveanna, a diversified home care platform headquartered in Atlanta, Georgia with locations in 38 states, uses these filings to report material events, financing arrangements, and financial results related to its pediatric and adult home-based healthcare services.
Among the key documents available are Current Reports on Form 8-K, where Aveanna describes material definitive agreements such as amendments to its first lien credit agreement, the creation and refinancing of term loan and revolving credit facilities, and the termination of a second lien credit agreement. Other 8-K filings report underwriting agreements for secondary offerings of common stock by existing stockholders, as well as the closing of those offerings.
Aveanna also uses Form 8-K to furnish press releases announcing quarterly and year-to-date financial results, preliminary financial data, and updated guidance. These filings often discuss non-GAAP measures such as EBITDA, Adjusted EBITDA, Normalized Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income, and Adjusted net income per diluted share, along with reconciliations to GAAP metrics. Additional 8-K items address board and governance matters, including amendments to stockholders’ agreements and changes in board composition.
On Stock Titan, users can view these AVAH filings alongside AI-powered summaries that explain the main points of each document in plain language. Real-time updates from EDGAR help surface new 8-Ks and, when filed, periodic reports such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements. The platform also highlights insider-related filings like Form 4 when available, allowing investors to review reported transactions by directors and officers in the context of Aveanna’s broader regulatory and financial disclosures.
Aveanna Healthcare (AVAH): insider sale reported. A 10% owner affiliated with J.H. Whitney disclosed sales on 10/24/2025 at $9 per share pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares; JHW Iliad Holdings LLC sold 224,553 shares; JHW Iliad Holdings II LLC sold 23,538 shares.
Following these transactions, reported indirect beneficial holdings included 19,292,787 shares by J.H. Whitney VII, L.P., 3,460,515 shares by JHW Iliad Holdings LLC, and 362,746 shares by JHW Iliad Holdings II LLC. Additional affiliated entities reported holdings as disclosed.
Aveanna Healthcare Holdings Inc. (AVAH)10,000,000 shares of common stock at $9.00 per share. The underwriters were led by Jefferies and J.P. Morgan, and the transaction closed on October 23, 2025.
The selling stockholders also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Aveanna did not issue any shares in this sale and did not receive proceeds, as all shares were sold by existing holders.
Aveanna Healthcare (AVAH): Form 4 discloses secondary sales by affiliated holders. On October 21, 2025, entities affiliated with the reporting person sold Aveanna common stock in an underwritten secondary offering at $9 per share. The disclosed sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC.
Following these transactions, the filing lists beneficial ownership positions such as 20,544,696 shares for J.H. Whitney VII, L.P., 15,523,809 shares for PSA Healthcare Investment Holdings LLC, 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) reported insider transactions on a Form 4 tied to an underwritten secondary sale by J.H. Whitney–affiliated entities on October 21, 2025. Reported sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC, each at $9 per share.
Following the transactions, reported indirect beneficial holdings included 20,544,696 shares for J.H. Whitney VII, L.P., 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC. Additional reported indirect holdings showed 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC.
Aveanna Healthcare (AVAH): insider sale reported. A reporting person affiliated with J.H. Whitney disclosed that J.H. Whitney VII, L.P. sold 8,346,059 shares of Aveanna common stock at $9 per share on 10/21/2025 in an underwritten secondary offering.
Following the transaction, 20,544,696 shares were reported as beneficially owned indirectly by J.H. Whitney VII, L.P. Additional indirect holdings were listed as 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC. The filing notes shared voting and dispositive power across related entities as described in the ownership structure.
Aveanna Healthcare Holdings Inc. announced a secondary offering by selling stockholders of 10,000,000 shares of common stock at $9.00 per share. The company will not receive any proceeds from these sales; proceeds go to the selling stockholders. Underwriters have a 30‑day option to purchase up to 1,500,000 additional shares.
The pricing implies an aggregate public offering of $90,000,000, with underwriting discounts of $4,050,000 and proceeds to selling stockholders of $85,950,000. Aveanna’s common stock trades on Nasdaq as AVAH. Shares outstanding were 208,259,393 as of June 28, 2025.
Aveanna also provided preliminary, unaudited Q3 results: revenue of $616–$624 million, net income of $11–$15 million, and Adjusted EBITDA of $77–$81 million, each described as growth over the prior year’s third quarter. Delivery of shares is expected on or about October 23, 2025.
Aveanna Healthcare Holdings (AVAH) announced a secondary offering in which the Selling Stockholders are offering 10,000,000 shares of common stock. The company stated it will not receive any proceeds from these sales. The underwriters have a 30‑day option to purchase up to 1,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The company included a preliminary third‑quarter update: revenue is expected at $616–$624 million (up 21.0%–22.6% year over year), net income at $11–$15 million (up 125.7%–135.0%), and Adjusted EBITDA at $77–$81 million (up 61.0%–69.3%). These figures are unaudited and subject to completion of financial closing procedures. A 90‑day lock‑up applies to the company, Selling Stockholders, directors and officers, subject to customary exceptions.
Shares outstanding were 208,911,373 as of October 15, 2025; this is a baseline figure, not the amount being offered.
Aveanna Healthcare Holdings Inc. furnished an 8-K to announce it issued a press release with preliminary results for the three-month period ended September 27, 2025. The press release, dated October 21, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02 is “furnished” and not “filed” under the Exchange Act, and will only be incorporated by reference into other filings if specifically stated.
Aveanna Healthcare Holdings Inc. furnished an investor presentation as part of a current report. On September 29, 2025, the company made a financial presentation available to investors and attached it as Exhibit 99.1 to this report. The presentation is also accessible through the Investors section of Aveanna’s website.
The company explains that it routinely uses its website and investor presentations to share important and time-sensitive information. The materials in this report, including Exhibit 99.1, are designated as “furnished” rather than “filed,” which means they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other SEC filings unless specifically referenced.
Aveanna Healthcare Holdings Inc. amended its first-lien credit agreement through a refinancing and incremental debt transaction. The company’s subsidiary put in place new first-lien term loans totaling $1.325 billion and expanded its revolving credit commitments to $250 million, replacing the prior term and revolving facilities. The new revolving facility matures on September 17, 2030, and the new term loans mature on September 17, 2032, with 1% annual amortization and original issue discount of 99.75% of par.
The term loans and revolver bear interest at the borrower’s option at Term SOFR plus a margin of 3.75% or a base rate plus 2.75%, with potential margin step-downs based on first-lien net leverage. Aveanna used proceeds from the new term loans to fully refinance its existing first-lien term loans and repay its $415 million second-lien term loan, as well as to pay accrued interest and fund working capital and general corporate purposes.